Tag - Rituximab

ISN Journal Editorial Selections on aHUS Management, Rituximab Therapy, Methylmalonic Acidemia, and Rare Kidney Diseases

Kidney International® Outcomes From the International Society of Nephrology Hemolytic Uraemic Syndromes International Forum  The 2023 ISN aHUS Forum brought together global experts to discuss key challenges in managing complement-mediated hemolytic uraemic syndromes (HUS), including nomenclature, biomarkers, and treatment protocols. Key areas for future research were identified, such as genetic predisposition, optimal complement inhibitor use, and improving...

December 9, 2024Journals, ResearchRead more...

A Cross-Continental Collaboration to Improve Pediatric Kidney Care Through the ISN Sister Renal Centers Program

The main objective of the eight-year ISN Sister Renal Centers (SRC) partnership was to improve the quality of pediatric kidney care at the Research & Clinical Institute for Pediatrics (RCIP), Pirogov Russian National Research Medical University, in Moscow, Russia, with support from the University Hospital (UZ) Leuven and Catholic (KU) Leuven University in Leuven,...

June 3, 2024Grants, News, Sister Renal CentersRead more...

Avacopan and Rituximab – A Promising Combination for Patients With ANCA-Associated Vasculitis

Read all global trial selections from the ISN-ACT initiative here. The “trial of the month” is available in several languages. In addition, selected clinical trials are demystified for the layperson. ISN-ACT Global Trials Focus Subgroup member Nikolay Bulanov summarizes the design and outcomes of one of the ISN-ACT Global Trials Focus’s latest trial selections. Efficacy and safety of...

June 3, 2024News, ResearchRead more...